Dual-targeting cyclic peptides of receptor-binding domain (rbd) and main protease (mpro) as potential drug leads for the treatment of sars-cov-2 infection

HIGHLIGHTS

• who: October and collaborators from the Institute of Pathogen Biology (CAMS), China Hebei Agricultural University, China have published the Article: Dual-targeting cyclic peptides of receptor-binding domain (RBD) and main protease (Mpro) as potential drug leads for the treatment of SARS-CoV-2 infection, in the Journal: (JOURNAL) of 28/08/2022

SUMMARY

Both of them feature an electrophilic warhead that forms a covalent_bond to SARS-CoV-2 Mpro, respectively (Owen et_al, 2021; Vandyck and Deval, 2021). Dockingbased virtual screening (DBVS) is a fast and efficient technique that has great potential to . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or Email

Password

Remember me

Lost your password?

If you don't have an account, you can create one here.